The Lancet Global Health published a paper by Medicines Patent Pool co-authors on expanding access to biotherapeutics in low- and middle-income countries (LMICs) through public health non-exclusive voluntary intellectual property licensing.

The key elements identified as relevant to support access to affordable biosimilars in LMICs through licensing include:

  • prioritising potential biotherapeutic targets according to their potential for public health impact
  • supporting biosimilar product and clinical development
  • facilitating biosimilars’ entry and use in LMICs

Click here to access the document

Co-authors include Sébastien Morin, Giulia Segafredo, Aditi Das, Meghmala Das, Nicola Loffredi, Amina Larbi, Elena Villanueva, Kim Mwamelo, Sandra Nobre, Manuele Piccolis and Esteban Burrone.